VC and Investment

India's BIRAC is propelling the country to global biotech leadership

India's BIRAC is propelling the country to global biotech leadership

As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024

Turnstone fires most staff in bid to extend runway

14 October 2024

Upstream Bio shares soar in impressive IPO

14 October 2024

CAMP4's turn to "dark side" shows promise, with $75 million IPO

11 October 2024

Latest fundraise points to undiminished appetite for AI in life sciences

11 October 2024

Today's issue

Sandoz reports strong third-quarter 2024 sales

Sandoz reports strong third-quarter 2024 sales

30 October 2024

Novartis’ Scemblix gains FDA approval in newly diagnosed CML

30 October 2024

Celltrion presents post hoc analysis of LIBERTY studies of Zymfentra

30 October 2024

Major milestone for Dewpoint with first development candidate announced

30 October 2024

GSK buys T cell-engager from Chimagen

29 October 2024

Green shoots of recovery bring biopharma hope

29 October 2024

Takeda posts positive mezagitamab results for patients with IgAN

29 October 2024

Refine Search

Kivu Bioscience raises $92 million

San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round led by Novo Holdings, which as of year-end 2011123 had total assets of 149 billion euros ($161 billion). 28 October 2024

Ottimo Pharma launches under former Seagen chief exec

Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024

Biostar prepares for $42 million IPO in Hong Kong

Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024

Agomab secures $89 million Series D financing

Belgian biotech Agomab Therapeutics today announced a $89 million (82.1 million euros) Series D financing round, with participation from new investors Sanofi and Invus 25 October 2024

Radiopharma start-up Alpha-9 Oncology secures $175 million

Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024

AvenCell raises $112 million in Series B financing

US clinical-stage biotech AvenCell Therapeutics announced that it has raised $112 million in Series B financing, which was led by global life sciences investor Novo Holdings. 23 October 2024

Seaport Therapeutics closes $225 million financing

Boston, USA-based Seaport Therapeutics has announced the closing of an oversubscribed $225 million Series B financing round, adding to the $100 million it pulled in along with its launch in April. 21 October 2024

India's BIRAC is propelling the country to global biotech leadership

As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024

LaNova Medicines secures $41 million in series C round

LaNova Medicines, a Shanghai-based biopharma company, has announced that it has secured 3 billion yuan ($41 million) in its series C funding round. 18 October 2024

Terray Therapeutics closes $120 million financing

California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024

Sanofi and Orano Med partner on next-gen radioligand therapies

Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024

Forbion’s largest fundraiser yet exceeds two billion euros

Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024

American Lung Association invests $22 million in research

The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024

China’s TenNor raises $41 million in series E financing

TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024

Nuclera secures $75 million for eProtein system

In Cambridge, UK, the protein specialist Nuclera has raised $75 million in a funding round led by Elevage Medical Technologies and backed by Patient Square Capital. 16 October 2024

Tolerance Bio launches with $17.2 million seed funding

Tolerance Bio has announced the closing of its oversubscribed $17.2 million seed financing round, led by Columbus Venture Partners. 16 October 2024

Akeso raises $250 million to fuel global development

In Hong Kong, Akeso Biopharma has successfully raised $250 million through a share placement, marking its second major fundraising effort of 2024. 15 October 2024

Inventiva announces financing of up to 348 million euros

French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024

Turnstone fires most staff in bid to extend runway

Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024

Upstream Bio shares soar in impressive IPO

Boston, USA-based Upstream Bio, a biotech developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, has made an impressive start to life as a public-listed company.00000 14 October 2024

12 3 4 5 6 7 8 9 10 Next page

Gilead gets favorable ruling in Roche arbitration

US biotech major Gilead Sciences said on Friday in a Security and Exchange Commission filing that an arbitration panel has ruled in its favor, rejecting patent infringement claims from Swiss drug giant Roche relating to its new hepatitis C drug, Sovaldi (sofosbuvir) which has already generated sales of $5.8 billion in its first six months of marketing. 17 August 2014

Ligand signs Captisol license deal with Avion Pharmaceuticals

Ligand Pharmaceuticals has signed a commercial license agreement with fellow USA-based Avion Pharmaceuticals, for the development and commercialization of four Captisol-enabled programs. Ligand’s shares gained 2.3% to $56.24 in after-hours trading yesterday. 15 August 2014

Dendreon shares fall as company warns of worry over debt repayment

Shares of US biotech firm Dendreon have fallen after it warned shareholders about debt problems. 13 August 2014

Mylan's 2nd-qtr earnings plunge on higher costs and product approval delays

US generics major Mylan has reported that profits dropped nearly 30% in the second quarter of 2014, despite higher revenue, as expenses rose and there were delays in US Food and Drug Administration approvals. 7 August 2014

Nura Bio closes further financing; names new CEO

US clinical-stage biotech Nura Bio today closed announced a more than $140 million in Series A financing.

Eisai enters inks research collaboration with Seed Thera

Seed Therapeutics has inked a collaboration with Japan’s Eisai to discover, develop and commercialize novel molecular glue degraders for multiple undisclosed neurodegeneration and oncology targets.

Previous page 72 73 74 7576

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze